

DAFTAR PUSTAKA

1. Vonk Noordegraaf A, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. *Eur Respir Rev.* 2016;25(139):4–11.
2. Hooper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. *Lancet Respir Med.* 2016;4(4):1–12.
3. Chang W, Weng S, Hsu C, Shih J, Wang J, Wu C. Prognostic factors in patients with pulmonary hypertension — a nationwide cohort study. *Am Hear Assoc.* 2016;1–11.
4. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol.* 2013;62(25 SUPPL.):34–9.
5. Frost AE, Badesch DB, Barst RJ, Benza RL, Gregory Elliott C, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: How REVEAL differs from historic and non-US contemporary registries. *Chest.* 2011;139(1):128–37.
6. Ronald J. Oudiz. Death in pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2013;188(3):267–9.
7. Dinarti LK, Anggrahini DW, Lilyasari O, Siswanto BB, Hartopo AB. Pulmonary arterial hypertension in Indonesia: Current status and local application of international guidelines. *Glob Heart.* 2021;16(1):1–11.
8. Hooper MM, Gibbs JSR. The changing landscape of pulmonary arterial hypertension and implications for patient care. *Eur Respir Rev.* 2014;23(134):450–7.
9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2016;37(1):67–119.
10. Maron BA, Galiè N. Pulmonary Arterial Hypertension Diagnosis, Treatment, and Clinical Management in the Contemporary Era HHS Public Access. *JAMA Cardiol.* 2016;1(9):1056–65.
11. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. *BMJ.* 2018;360:1–27.
12. Hooper MM, Ghofrani HA, Grünig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. *Dtsch Arztebl Int.* 2017;114(5):73–84.
13. Condon DF, Nickel NP, Anderson R, Mirza S, De VA, Perez J. Open peer review The 6th World Symposium on Pulmonary Hypertension: what’s old is new. *F1000Research.* 2019;8:1–8.
14. Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: From diagnosis to prognosis. *J Am Soc Echocardiogr.* 2013;26(1):1–14.
15. Chan SY, Loscalzo J. Pulmonary Arterial Hypertension. *Orphanet J Rare Dis.* 2013;1–28.
16. Parul Pahal; Sandeep Sharma. Idiopathic Pulmonary Artery Hypertension. *Treasure Island: StatPearls;* 2021.

17. Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, et al. Pulmonary arterial hypertension. *Orphanet J Rare Dis.* 2013;8(1):1–28.
18. Orcholski ME, Yuan K, Rajasingh C, Tsai H, Shamskhou EA, Dhillon NK, et al. Drug-induced pulmonary arterial hypertension: A primer for clinicians and scientists. *Am J Physiol - Lung Cell Mol Physiol.* 2018;314(6):L967–83.
19. Peacock A. Pulmonary hypertension. *Eur Respir Rev.* 2013;22(127):20–5.
20. Sibomana JP, Campeche A, Carvalho-Filho RJ, Correa RA, Duani H, Pacheco Guimaraes V, et al. Schistosomiasis pulmonary arterial hypertension. *Front Immunol.* 2020;11(December):1–18.
21. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL registry. *Chest.* 2010;137(2):376–87.
22. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. *Nat Rev Cardiol.* 2017;14(10):603–14.
23. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2012;186(9):892–6.
24. Kawut SM, Lima JAC, Barr RG, Chahal H, Jain A, Tandri H, et al. Sex and race differences in right ventricular structure and function: The multi-ethnic study of atherosclerosis-right ventricle study. *Circulation.* 2011;123(22):2542–51.
25. George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S. Pulmonary hypertension surveillance United States, 2001 to 2010. *Chest.* 2014;146(2):476–95.
26. Schiess R, Senn O, Fischler M, Huber LC, Vatandaslar S, Speich R, et al. Tobacco smoke: A risk factor for pulmonary arterial hypertension? A case-control study. *Chest.* 2010;138(5):1086–92.
27. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. *Clin Toxicol.* 2018;56(9):801–9.
28. Memon HA, Park MH. Pulmonary Arterial Hypertension in Women. *Methodist Debakey Cardiovasc.* 2017;13(4):224–37.
29. Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, et al. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. *Chest.* 2018;154(4):872–81.
30. Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, et al. Pathogenesis of pulmonary arterial hypertension: Lessons from cancer. *Eur Respir Rev.* 2013;22(130):543–51.
31. Falk E, Fuster V. Pulmonary Hypertension. In: *Hurst's The Heart.* 14th ed. New York: McGraw-Hill; 2017. p. 17885–1809.
32. Rubin LJ. Primary Pulmonary Hypertension. *N Engl J Med.* 2014;336.
33. Rubenfire M, Bayram M, Hector-Word Z. Pulmonary hypertension in the critical care setting: Classification, pathophysiology, diagnosis, and management. *Crit Care Clin.* 2007;23(4):801–34.
34. Kiely DG, Elliot CA, Sabroe I, Condliffe R. Pulmonary hypertension: Diagnosis

- and management. *BMJ*. 2013;346(7904):1–12.
35. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension. *Chest*. 2004;126(1):14S-34S.
 36. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al. Use of ECG and other simple non-invasive tools to assess pulmonary hypertension. *PLoS One*. 2016;11(12):1–12.
 37. Huffman M, McLaughlin V V. Evaluation and Diagnosis of Pulmonary Arterial Hypertension. *US Cardiol Rev*. 2006;3(1):30–2.
 38. Mortani Barbosa EJ, Gupta NK, Torigian DA, Geftter WB. Current role of imaging in the diagnosis and management of pulmonary hypertension. *Am J Roentgenol*. 2012;198(6):1320–31.
 39. Knutson JS. A Simple Echocardiographic Method To Estimate Pulmonary Vascular Resistance Alexander. *Bone*. 2014;23(1):1–7.
 40. Augustine DX, Augustine DX, Coates-bradshaw LD, Willis J, Harkness A, Ring L, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2018;5(3):11–24.
 41. Chemla D, Humbert M, Sitbon O, Montani D, Hervé P. Systolic and mean pulmonary artery pressures: Are they interchangeable in patients with pulmonary hypertension? *Chest*. 2015;147(4):943–50.
 42. Ahmed M, Dweik RA, Tonelli AR. What is the best approach to a high systolic pulmonary artery pressure on echocardiography? *Cleve Clin J Med*. 2016;83(4):256–60.
 43. Charalampopoulos A, Gibbs SRJ. Diagnosis and treatment of pulmonary hypertension. *Eur Cardiol*. 2012;8(3):213–8.
 44. Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. *Lancet Respir Med*. 2021;9(10):1185–91.
 45. Widrich J, Shetty M. Physiology, Pulmonary Vascular Resistance. *StatPearls*. 2021
 46. Rosenkranz S, Preston IR. Right heart catheterisation: Best practice and pitfalls in pulmonary hypertension. *Eur Respir Rev*. 2015;24(138):642–52.
 47. Thomaz AM, Kajita LJ, Aiello VD, Zorzanelli L, Galas FRBG, Machado CG, et al. Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments. *Pulm Circ*. 2019;9(3):1–13.
 48. Kaymaz C, Ozturk S, Akbal OY, Poci N, Aktemur T, Yilmaz F, et al. the Pulmonary Vascular Resistance and Pulmonary Vascular Resistance To Systemic Resistance Ratio But Not Diastolic Pulmonary Gradient, May Predict Survival in Patients With Pulmonary Hypertension: Insights From a Single-Center Study. *J Am Coll Cardiol*. 2015;65(10):A1562.
 49. Tuder RM, Archer SL, Dorfmueller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 SUPPL.).

50. Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: A pharmacotherapeutic update. *Curr Cardiol Rep.* 2019;21(11).
51. Review CE. Pulmonary arterial hypertension: Screening, management, and treatment. *Pubmed.* 2013;(117).
52. Katzung BG, Masters SB, Trevor AJ. Obat yang digunakan pada gagal jantung. In: *Farmakologi Dasar & Klinik.* McGraw-Hill Companies; 2012. p. 219, 326, 336.
53. Laporan Nasional Riskesdas 2018. Jakarta; 2018.
54. Trow TK, McArdle JR. Diagnosis of Pulmonary Arterial Hypertension. *Clin Chest Med.* 2007;28(1):59–73.
55. Nugraha IW, Irawan B, Dinarti LK. Recurrent hemoptysis in patient with primary pulmonary hypertension – A case report and literature review. *ACI (Acta Cardiol Indones.* 2017;3(1):45.
56. McLaughlin V V., McGoon MD. Pulmonary arterial hypertension. *Circulation.* 2006;114(13):1417–31.
57. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: Epidemiology and registries. *J Am Coll Cardiol.* 2013;62(25 SUPPL.).
58. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. *Clin Sci.* 2011;120(9):357–75.
59. Petrovic A, Seimetz M, Mamazhakypov A, Pak O, Sydykov A, Kosanovic D. Pulmonary arterial hypertension and aging: Is there a connection? *Pulmonary Vascular Research Institute (PVRI).* 2016.
60. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? *Proc Am Thorac Soc.* 2006;3(8):680–6.
61. Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, et al. Oestrogen receptor alpha in pulmonary hypertension. *Cardiovasc Res.* 2015;106(2):206–16.
62. Patel V, Khaped K, Solanki B, Patel A, Rathod H, Patel J. Profile of pulmonary hypertension patients coming to civil hospital, Ahmedabad. *Int J Res Med.* 2013;2(1):94–7.
63. Hakiki G, Supriyanto S. Profil Perempuan Indonesia 2018. *Kementerian Pemberdayaan Perempuan dan Perlindungan Anak.* 2018;3–100.
64. Penduduk 15 Tahun Ke Atas Menurut Status Pekerjaan Utama 1986 - 2021. 2021.
65. Hurewitz AN, Bergofsky EH. Primary pulmonary hypertension. *Cardiol Board Rev.* 1987;4(7):46–58.
66. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: A comparison between children and adults. *Eur Respir J.* 2011;37(3):665–77.
67. Chazova IY, Martynyuk T V, Valieva ZS, Gratsianskaya SY, Aleevskaya AM, Zorin A V, et al. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. 2020;2020.
68. Guiot J, Parzibut G, Weber T, Davin L, Dulgheru R, Lancellotti P, et al. Pulmonary arterial hypertension. *Rev Med Liege.* 2019;74(3):139–45.
69. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, et al. United States Pulmonary Hypertension Scientific Registry: Baseline

- Characteristics. *Chest*. 2021;159(1):311–27.
70. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: A descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc Disord*. 2020;20(1):1–11.
 71. Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. *Eur Respir J*. 2006;27(1):114–20.
 72. Hall JE. *Guyton and Hall Textbook of Medical Physiology*. 13th ed. Elsevier; 2015.
 73. Bouchery-Bardet H, Creveuil C, Bauer F, Beygui F, Champ-Rigot L, Saloux E, et al. Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis. *Respir Med*. 2017;132:42–9.
 74. Irwin DC, Garat C V., Crossno JT, Maclean PS, Sullivan TM, Erickson PF, et al. Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia. *Pulm Circ*. 2014;4(4):638–53.
 75. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ, et al. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. *Int J Cardiol*. 2007;120(2):198–204.
 76. Ullah W, Minalyan A, Saleem S, Nadeem N, Abdullah HM, Abdalla A, et al. Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension: A systematic review and meta-analysis. *IJC Hear Vasc*. 2020;29:100568.
 77. Tonelli AR, Baumgartner M, Alkukhun L, Minai OA, Dweik RA. Electrocardiography at diagnosis and close to the time of death in pulmonary arterial hypertension. *Ann Noninvasive Electrocardiol*. 2014;19(3):258–65.
 78. Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. *Pulm Circ*. 2018;8(2):4–11.
 79. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: Pathogenesis, prognosis and management. *Arrhythmia Electrophysiol Rev*. 2018;7(1):43–8.
 80. Waligóra M, Tyrka A, Miszański-Jamka T, Urbańczyk-Zawadzka M, Podolec P, Kopeć G. Right atrium enlargement predicts clinically significant supraventricular arrhythmia in patients with pulmonary arterial hypertension. *Hear Lung*. 2018;47(3):237–42.
 81. Nagle RE. *Pathophysiology of Heart Disease*. Vol. 64, Postgraduate Medical Journal. 1988. 910–910 p.
 82. Meyer M. Left ventricular atrophy in pulmonary arterial hypertension: A sinister dexter conundrum. *J Am Coll Cardiol*. 2014;64(1):38–40.
 83. Bernardo RJ, Haddad F, Couture EJ, Hansmann G, de Jesus Perez VA, Denault AY, et al. Mechanics of right ventricular dysfunction in pulmonary arterial

- hypertension and heart failure with preserved ejection fraction. *Cardiovasc Diagn Ther.* 2020;10(5):1580–603.
84. Daines B, Rao S, Hosseini O, Prieto S, Abdelmalek J, Elmassry M, et al. The clinical associations with cardiomegaly in patients undergoing evaluation for pulmonary hypertension. *J Community Hosp Intern Med Perspect.* 2021;11(6):787–92.
 85. Yang S, Lei S, Peng F, Wu S jie. Detection of Pulmonary Hypertension by Combining Echocardiography and Chest Radiography. *Acad Radiol.* 2022;29(8):S23–30.
 86. Sinnatamby CS. *Last's Anatomy: Regional and Applied.* 12th ed. Churchill Livingstone; 2011. 213 p.
 87. Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, et al. Pulmonary arterial dilatation in pulmonary hypertension: Prevalence and prognostic relevance. *Cardiology.* 2012;121(2):76–82.
 88. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circ Hear Fail.* 2011;4(3):257–65.
 89. Allison JD, Macedo FY, Hamzeh IR, Birnbaum Y. Correlation of right atrial enlargement on ECG to right atrial volume by echocardiography in patients with pulmonary hypertension. *J Electrocardiol.* 2017;50(5):555–60.
 90. Marra AM, Naeije R, Ferrara F, Vriza O, Stanziola AA, D'Alto M, et al. Reference ranges and determinants of tricuspid regurgitation velocity in healthy adults assessed by two-dimensional doppler-echocardiography. *Respiration.* 2018;96(5):425–33.
 91. Montané BE, Fiore AM, Reznicek EC, Jain V, Jellis C, Rokadia H, et al. Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. *Chest.* 2021;160(6):2209–19.
 92. Chen L, Larsen CM, Le RJ, Connolly HM, Pislaru S V., Murphy JG, et al. The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension. *Clin Respir J.* 2018;12(4):1572–80.
 93. Casa LDC, Dolensky JR, Spinner EM, Veledar E, Lerakis S, Yoganathan AP. Impact of pulmonary hypertension on tricuspid valve function. *Ann Biomed Eng.* 2013;41(4):709–24.
 94. Lilyasari O, Subekti Y, Atika N, Dinarti LK, Putri S, Opitasari C, et al. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. *BMC Health Serv Res.* 2019;19(1):1–9.